U.S. market Closed. Opens in 10 hours 10 minutes

TARO | Taro Pharmaceutical Industries Ltd. Stock Fundamentals

(Stock Exchange: NYSE)
Analyzing fundamentals for TARO we got that it has weak fundamentals where Valuation is considered to be fairly valued, Profitability is very poor, Growth is desperately bad and Health is strong.

Valuation (52%)

Company Industry
P/E Ratio (TTM) 29.99 16.83
PEG Ratio (TTM) 1.66 -22.40
P/S Ratio (TTM) 2.57 5.41
P/B Ratio (TTM) 0.90 4.28
P/FCF Ratio (TTM) 21.77 8.05
Price to 5YR AVG Earnings Ratio -448.36 28.12
Price to 5YR AVG FCF Ratio 41.81 20.99

Profitability (35%)

Company Industry
ROA (TTM) 2.49% 2.55%
ROE (TTM) 3.05% 16.58%
Net Profit Margin (TTM) 8.56% -13.15%
ROIC 5YR AVG 16.40% 9.71%

Growth (30%)

4QTR AVG 3YR AVG 5YR AVG
EPS 36.01% -54.20% -21.69%
Revenue 3.17% -5.45% -0.89%
Net Income 35.34% -54.29% -21.50%
Cash Flow 108.21% -181.99% -21.80%

Health (61%)

Company Industry
Current Ratio (TTM) 3.61 2.49
Quick Ratio (TTM) 2.93 1.85
D/E Ratio (TTM) N/A -0.31
Interest Coverage (TTM) N/A 11.90
Piotroski F-Score 8 6
Altman Z-Score 3.57 4.64
LTL to 5YR AVG FCF N/A 4.62
Shares Outstanding Growth 5YR AVG -0.73% 30.07%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙